DSpace at RU >

Browsing by Author Gibb, D.

Full Text	Issue Date	Title	Author(s)
	2010	Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3-<36 months.	Jacqz-Aigrain, E.; Harrison, L.; Zhao, W.; Compagnucci, A.; Castro, H., et al
	2007	Children with HIV are not small adults : what is different in pharmacology?	L'homme, R.F.A.; Warris, A.; Gibb, D.; Burger, D.M.
	2006	A randomized controlled trial of genotypic HIV drug resistance testing in HIV-infected children: the PERA (PENTA 8) trial.	Green, H.; Gibb, D.; Compagnucci, A.; Giacomet, V.; Rossi, A. de, et al
	2006	Adherence and acceptability of once daily Lamivudine and abacavir in human immunodeficiency virus type-1 infected children.	LePrevost, M.; Green, H.; Flynn, J.; Head, S.; Clapson, M., et al
	2005	Plasma pharmacokinetics of once- versus twice-daily lamivudine and abacavir: simplification of combination treatment in HIV-1-infected children (PENTA-13).	Bergshoeff, A.S.; Burger, D.M.; Verweij, C.; Farrelly, L.; Flynn, J., et al
	2004	Maintaining the nelfinavir trough concentration above 0.8 mg/L improves virologic response in HIV-1-infected children.	Burger, D.M.; Bergshoeff, A.S.; Groot, R. de; Gibb, D.; Walker, S., et al
	2004	Maintaining the nelfinavir through concentration above 0.8 mg/L improves virologic response in HIV-1-infected children.	Burger, D.M.; Bergshoeff, A.S.; Groot, R. de; Gibb, D.; Walker, S., et al